Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Lazard Asset Management LLC

Lazard Asset Management LLC cut its holdings in Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 86.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,378 shares of the biotechnology company's stock after selling 8,772 shares during the period. Lazard Asset Management LLC's holdings in Blueprint Medicines were worth $118,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. R Squared Ltd purchased a new stake in shares of Blueprint Medicines in the 4th quarter worth about $51,000. Headlands Technologies LLC purchased a new stake in shares of Blueprint Medicines in the 4th quarter worth about $65,000. Thematics Asset Management purchased a new stake in shares of Blueprint Medicines in the 4th quarter worth about $72,000. Covestor Ltd lifted its holdings in Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock valued at $85,000 after purchasing an additional 375 shares in the last quarter. Finally, Asset Management One Co. Ltd. purchased a new position in Blueprint Medicines in the 4th quarter valued at about $88,000.

Blueprint Medicines Trading Down 1.4%

BPMC traded down $1.44 on Tuesday, reaching $100.06. 709,926 shares of the company's stock were exchanged, compared to its average volume of 781,125. The company's 50 day moving average is $90.99 and its 200-day moving average is $94.58. The company has a market cap of $6.46 billion, a price-to-earnings ratio of -92.65 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.80 and a current ratio of 2.85.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The business had revenue of $149.41 million for the quarter, compared to analyst estimates of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The firm's revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the company posted $1.40 EPS. Equities analysts predict that Blueprint Medicines Co. will post -1.28 earnings per share for the current year.

Insider Buying and Selling

In other Blueprint Medicines news, insider Ariel Hurley sold 2,752 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $103.13, for a total value of $283,813.76. Following the completion of the sale, the insider now owns 16,944 shares of the company's stock, valued at $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $100.51, for a total transaction of $228,559.74. Following the completion of the sale, the chief operating officer now directly owns 64,718 shares of the company's stock, valued at $6,504,806.18. This trade represents a 3.39% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,777 shares of company stock valued at $1,256,490. 4.21% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have issued reports on BPMC shares. HC Wainwright restated a "buy" rating and issued a $135.00 target price on shares of Blueprint Medicines in a report on Friday, May 2nd. Wall Street Zen upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. Needham & Company LLC reduced their target price on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating on the stock in a report on Monday, April 28th. JPMorgan Chase & Co. upped their target price on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Finally, Scotiabank started coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They issued a "sector outperform" rating and a $150.00 target price on the stock. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Blueprint Medicines currently has a consensus rating of "Moderate Buy" and an average price target of $126.56.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.